Consegna picks manufacturer for nasal dilator
Consegna (ASX:CGP) has selected a global manufacturing partner for its Turbine nasal dilator product, which is due to reach the market in the fourth quarter.
ChinaMed Manufacturing will manufacture and package Turbine products, scaling up production in time for the Q4 launch.
Consegna plans to debut the products into the Australian online sporting and physical recreation goods industry, a market which was worth an estimated $765 million in FY13.
The Turbine nasal dilator is part of Consegna’s BreatheAssist range. It was developed for the sports market in consultation with top Australian athletes.
The company recently conducted a pilot study of the device with Australian athletes, finding that two thirds felt they were able to get more air into their lungs while training with the device and that 80% would purchase such a device online.
Other target markets for the BreatheAssist technology include snoring management, olfactory or weight management, sleep apnoea and drug delivery.
Consegna CEO Michael Johnson said ChinaMed has the scale and ability “to not only meet our needs in our consumer markets, but brings a strong track record of complying with the rigorous regulatory environments of sleep and drug delivery.”
Consegna shares were trading 2.08% higher at $0.049 as of around 1 pm on Tuesday.
The Australian Government has secured 450,000 doses of the new third-generation monkeypox vaccine...
Moderna's COVID-19 vaccine will be available to children aged six months to less than five...
A research team led by Edith Cowan University (ECU) has found a way to make lung cancer treatment...